`
`
`
`
`
`
`
`
`
`
`
`
`
`Kelly E. Farnan
`Director
`302‐651‐7705
`Farnan@rlf.com
`
`
`
`May 4, 2016
`BY CM/ECF AND HAND DELIVERY
`The Honorable Richard G. Andrews
`United States District Court
`District of Delaware
`844 N. King Street
`Wilmington, DE 19801
`
`
`Re: Hospira, Inc. v. Amneal Pharmaceuticals LLC, C.A. No. 15-697-RGA
`
`
`Dear Judge Andrews:
`
`
`I write on behalf of Defendant Amneal Pharmaceuticals LLC (“Amneal”) in accordance
`with District of Delaware Local Rule 7.1.2(b) to provide the Court with supplemental authority
`relevant to issues raised in the Joint Claim Construction Brief (D.I. 44). Specifically, attached as
`Exhibit A is U.S. Patent No. 9,320,712 (the “’712 patent”) which issued to Plaintiff Hospira, Inc.
`on April 26, 2016. The ’712 patent issued on the same day that Amneal served its sur-reply
`brief and Amneal was not aware of it sufficiently in advance of the deadline to address it in the
`briefing that has been submitted to the Court. Amneal believes that the ’712 patent, which is part
`of the intrinsic record of the other patents-in-suit, contains disclosure relevant to the construction
`of at least the term “dexmedetomidine” and Amneal will briefly address the ’712 patent at the
`claim construction hearing scheduled for May 12, 2016.
`
`If Your Honor has any questions concerning the foregoing, counsel remains available at
`the Court’s convenience.
`
`
`
`
`
`
`cc:
`
`
`RLF1 14471592v.1
`
`
`
`
`
`
`
`Counsel of Record (by CM/ECF)
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`Respectfully,
`
`/s/ Kelly E. Farnan
`
`Kelly E. Farnan (#4395)
`
`